In some patients who died of Covid-19 and respiratory failure, a jelly was formed in the lungs and now researchers have established that the active agent in the jelly can be the key to new effective therapies.

"There are already therapies that either slow down the body's production of this jelly or break down the jelly through an enzyme," said study researcher Urban Hellman from Umeå University in Sweden.